AGM/EGMMay 20, 2026, 04:14 PM
Rigel Pharmaceuticals Stockholders Approve 860,000 New Shares for Equity Plans
AI Summary
Rigel Pharmaceuticals' stockholders approved amendments to the 2018 Equity Incentive Plan and the 2000 Employee Stock Purchase Plan at the Annual Meeting on May 14, 2026. These amendments collectively add 860,000 shares of common stock authorized for issuance under the plans. Additionally, stockholders elected three directors, approved executive compensation on an advisory basis, and ratified Ernst & Young LLP as the independent registered public accounting firm for 2026.
Key Highlights
- Stockholders approved adding 500,000 shares to the 2018 Equity Incentive Plan.
- Stockholders approved adding 360,000 shares to the 2000 Employee Stock Purchase Plan.
- The Amended 2018 Equity Incentive Plan was approved with 6,497,964 votes For.
- The Amended 2000 Employee Stock Purchase Plan was approved with 9,840,922 votes For.
- Alison Hannah, Walter Moos, and Raul Rodriguez were elected as directors.
- Executive compensation was approved on an advisory basis with 9,013,480 votes For.
- Ernst & Young LLP was ratified as independent auditor with 12,590,773 votes For.
Price Impact
More from RIGL